All News
We should aim for early treatment and good retention in ax-SpA to prevent structural evolution. >12 months of TNFi treatment in the previous 2 years associated w/ ⬇️ radiographic progression of SIJ in r- and nr-axSpA in GESPIC, #Abst0174 @RheumNow #ACR21 https://t.co/2V1q4dUwFO https://t.co/lxQU4zAP1I
Aurelie Najm AurelieRheumo ( View Tweet)
Retrospective French study found adding JAKi may be helpful in refractory AOSD. No complete response noted and no beneficial effect as monotherapy. Possible difference between JAKi? Abs 0195 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/J8kLJpJ39o https://t.co/aVsfCQ8CyV
Dr. Rachel Tate uptoTate ( View Tweet)
Our latest article on outcomes of patients with vasculitis and PMR and COVID-19 published in @TheLancetRheum . @rheum_covid project with co-leads @SattuiSEMD and @EBRheum . https://t.co/8NTAafdYRA
Richard Conway RichardPAConway ( View Tweet)
#Fatigue is common in pts w/ #PsA- what is the impact on short-term disability?
Study of ~1200 pts finds greater annual short-term disability in pts with PsA & fatigue than w/o fatigue. Impact on QoL, work & socioeconomic costs.
@RheumNow #ACR21 Abs#0239
https://t.co/9yNBOovm2L https://t.co/l4tn0TSld1
Mrinalini Dey DrMiniDey ( View Tweet)
📌Pre-Test Probability in GCA
ESR/CRP can be normal:
~10% of pts at diagnosis
-20-40% at time or relapse
#ACR21 #ACRAmbassador #RheumTwitter https://t.co/kenaD31pYa
Nina Couette RheumDr_Nina ( View Tweet)
Machine learning predicted lupus nephritis in #SLE patients in real world data #ACR21 @RheumNow #abst0324 https://t.co/67HBT7F2GO
Bella Mehta bella_mehta ( View Tweet)
Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Most MPO+, but also rarely seen with PR3+. 47% ⬆️ risk of death. Abstr#0430 #ACR21 @RheumNow https://t.co/6MnxqW92bz
Richard Conway RichardPAConway ( View Tweet)
Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare more patients biopsy? Abstr#0001 #ACR21 @RheumNow https://t.co/ikNXCEOeuj
Richard Conway RichardPAConway ( View Tweet)
Don't wait!
DR. Petri wants us to change paradigm of how we treat aggressive lupus nephritis: early, aggressive, and multimodal. Does not matter if you add on VCS or BLMB, just don't treat LN with MMF monotherapy.
#ACR21 #GreatDebate @rheumnow https://t.co/ebSiic095h
TheDaoIndex KDAO2011 ( View Tweet)
#Flu vaccine coverage remains low in patients with #rheumatoidarthritis.
Results from @earlyarthritis Abs#0141
https://t.co/DoZl5xyq2Q
How can we increase vaccine uptake in our patients?
@RheumNow https://t.co/nldA63EcVW
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR2021
Remember, one reason belimumab is so safe is that it does not completely deplete B cells. Particularly important in times of COVID19.
Dr. Petri #GreatDebate @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ
Richard Conway RichardPAConway ( View Tweet)
Cluster analysis in axSpA pts classified 2 groups (predominantly axial vs peripheral dz) and showed lower TNFi drug survival rates in those with prominent extra-axial manifestations. Abs 0365 #ACR21 #RheumNow @RheumNow https://t.co/ArgQ7mNqeD https://t.co/XqF7rPneMV
Dr. Rachel Tate uptoTate ( View Tweet)
🔥 Ready for the next level of imaging? The radio-labelled tracer binding to integrin αvβ3 99mTc-maraciclatide is able to detect hypervascularization in RA joints and correlates w/ PDUS findings
⭐️ Sens 78%
⭐️ See 91%
Fancy, yet more invasive than US! #Abst0174 @RheumNow #ACR21 https://t.co/eCOxjJsERh
Aurelie Najm AurelieRheumo ( View Tweet)
3/4 axSpA EMAS pts had/perceived to have employment challenge. Poor physical/mental health, lower education, hx job change due to axSpA associated w/difficulties/perceived difficulties. Earlier dx/rx AND advocacy needed. Abs 0366 #ACR21 #RheumNow @RheumNow https://t.co/dlGhOymxVQ https://t.co/CWD6U1vRE0
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR21 Previews from Creaky Joints
https://t.co/9T3EepV3CE https://t.co/Ay0A3hWSxU
Links:
Dr. John Cush RheumNow ( View Tweet)
Danish axSpA study shows pts in remission on TNFi may be able to taper and remain in remission at the 2 year mark. Abs0364 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/LBR5cSThQY https://t.co/sCqqhuBaTS
Dr. Rachel Tate uptoTate ( View Tweet)
Gender differences in AS pts?
IL-23R, IL-12R, IL-6R, JAK, STAT and TYK2 ⬇️regulated in men
Small study of 20 pts, but could it guide targeted therapy based on gender?🤔
Abs#0050
https://t.co/OQHQCCzfuC
#ACR21
@RheumNow
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Dr Adachi presents ⬆️BMD gain with denosumab than risedronate in RA. Non-significant reduction in fractures (very small numbers) Interesting, but need to see fracture benefit in larger study to justify dmab as first line Abstr#0445 #ACR21 @RheumNow https://t.co/GgaS9JZGzb
Richard Conway RichardPAConway ( View Tweet)
"I don't want rheumatologist only use BLMB and nephrologist using only VCS."
- Dr. M Petri on how we should work together with nephrologists on managing lupus nephritis.
(She did give a final dig & added "BLMB can be used with any GFR")
#ACR21 #GreatDebate @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)